Introduction
Atazanavir (ATV) is an azapeptide of the protease inhibitor (PI) drug class because it selectively inhibits HIV genotype I (HIV-I) protease, an enzyme critical for HIV-1 virion maturation. ATV is typically administered in combination with a pharmacokinetic (PK) enhancer (also known as a 'booster') to improve its PK profile and two different nucleoside reverse transcriptase inhibitors as a part of combination antiretroviral (ART) therapy [1, 2] . Once-dailydosing, fewer metabolic side effects compared with other PIs, and a high barrier to drug resistance make ATV, particularly when boosted, a good option for HIV-1-positive individuals with poor adherence, cardiovascular diseases, or diabetes mellitus [3] [4] [5] [6] . Genetic variants in the genes encoding the principal enzymes involved in the metabolism of ATV, which are also central to the metabolism of many commonly prescribed drugs, have been found to be associated with adverse events and changes in the PKs of ATV. Common adverse effects associated with ATV include hyperbilirubinemia, cosmetic jaundice, nephrolithiasis, and cholelithiasis [7] . The updated Health and Human Services 2017 'Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents' now favors integrase strand transfer inhibitor regimens over PIs, including ATV, as the preferred initial regimen for treatment-naive patients. Atazanavir/ritonavir (ATV/r) with two nucleoside reverse transcriptase inhibitors is a 'Recommended, Alternative, and Other Antiretroviral Regimen Options for Treatment-Naive Patients', but may still be 'the preferred regimen for some patients' [6] .
Pharmacokinetics
ATV is rapidly absorbed and the peak ATV concentration (C max ) is reached between 2 and 2.5 h postdose. ATV absorption is improved when it is taken with food. The primary route of ATV elimination is through bile (79% of administered dose) and the secondary route is through urine (13% of administered dose excreted as metabolites). There are well-established PK differences when comparing between races, men and women, and HIV-1-positive patients compared with HIV-1-negative patients that are yet to be explained [3, 8] . In addition, there are also documented differences between men and women with respect to time to virologic failure, although the results of studies are contradictory [9] [10] [11] .
ATV is primarily and extensively metabolized by the cytochrome P450, family 3, subfamily A (CYP3A) polypeptide isoenzymes 4 and 5 (CYP3A4/5) [8] . It is not known whether it enters cells through diffusion or whether influx is mediated by specific transporters. The organic anion transporter protein 1B1 (OATP1B1), which is encoded by the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene, is known to facilitate the uptake of conjugated bilirubin from blood and possibly unconjugated bilirubin and ritonavir. According to the results of at least one in-vitro study, ATV may be an inhibitor of OATP1B1 [12] . However, the effect of any polymorphisms of SLCO1B1 in patients administered ATV may actually be because ritonavir may be an inhibitor of OATP1B1, rather than ATV, although this is not yet established [12] [13] [14] [15] . ATV may be a substrate of P-glycoprotein that is encoded by the ATP-binding cassette subfamily B member 1 (ABCB1) gene as well as an inhibitor, although more evidence may be needed to clarify this relationship [16] [17] [18] [19] [20] . None of the studies discussed here have shown a genetic association between ATV and the nuclear receptor subfamily 1 group I member 2 (NR1I2) gene that encodes the pregnane X receptor; variants in this gene have been investigated with respect to ATV PK, possibly because it regulates the expression of CYP3A4, SLCO1B1, and ABCB1 [19, 21, 22] . Figure 1 shows the pharmacodynamic and PK pathways of ATV and a fully interactive version of these pathways can be accessed at PharmGKB (https://www.pharmgkb.org/ pathway/PA166170503).
The US Food and Drug Administration (FDA)-approved drug label for ATV indicates that the major biotransformation pathways of ATV are mono-oxygenation and dioxygenation, whereas minor biotransformation pathways include glucuronidation, N-dealkylation, hydrolysis, oxygenation, and dehydrogenation [23] . Four studies investigating biotransformation pathways of ATV confirm that mono-oxidation is a major pathway of ATV biotransformation, with two explicitly identifying the structures of one or two mono-oxidation products (M1, M2), such as 'a hydroxylated phenylbutane moiety', whereas two others solely identified multiple 'mono-oxidated' metabolites of ATV without specifying their structures. All four studies detected the presence of metabolites that were the product of carbamate hydrolysis on the prime and nonprime sides of ATV (M3, M4), and three studies detected one N-dealkylation metabolite (M5) (Fig. 1 ) [24] [25] [26] [27] . None of the studies, which assessed metabolites in human plasma, human liver microsomes, hepatocytes, or in mouse feces and urine, reported identifying glucuronidated ATV-metabolites. In addition, no ATV glucuronide structures are deposited in PubChem, which contradicts information on the FDAapproved drug label. When unboosted, mono-oxidation and oral clearance (CL/F) of ATV may occur more rapidly in those individuals who carry at least one functional version of CYP3A5 compared with individuals who carry no functional copies because of homozygosity of CYP3A5*3 (c.219-237 C > T at rs776746), CYP3A5*6 (c. 624 C > T at rs10264272), or CYP3A5*7 (c.1035_1036 insT at rs41303343) [26, 28, 29] .
Ritonavir as a pharmacokinetic enhancer of atazanavir
Ritonavir is also a PI, but its ability to block CYP3A-mediated metabolism of ATV makes it an effective PK enhancer (or 'booster'). When boosted with ritonavir (300 mg ATV and 100 mg ritonavir; ATV/r), the PK profile of ATV is improved and individual differences in ATV PKs are decreased [8] . Treatment with unboosted ATV is approved by the FDA for specific cases, although the European Medicines Agency does not formally approve it [30] . ATV administered without a PK enhancer is not a recommended course of therapy for treatment-naive individuals, individuals with a very high viral load (e.g. 100 000 ≥ copies HIV-1 RNA/ml) [6, 23] , patients with previous virologic failure (>50 copies HIV-1 RNA/ml), or pregnant women. ATV without a PK enhancer may be recommended in special cases such as to reduce pill burden, improve treatment adherence, or to prevent long-term toxicities associated with ritonavir in individuals with hepatic impairment [30] .
The ATV drug label advises against coadministration of unboosted ATV with tenofovir as tenofovir had been shown to decrease ATV exposure, mostly through increased clearance. However, current consensus on the effect of tenofovir on ATV exposure in patients administered ATV/r is less clear: some studies continue to find that tenofovir is associated with a decrease in ATV exposure [30] [31] [32] [33] [34] , whereas others report no significant negative effects on ATV exposure in patients administered ATV/r [35] [36] [37] [38] [39] . In a randomized, controlled pilot study in which patients were switched to ATV without ritonavir, a pharmacogenetically informed dosing algorithm helped patients maintain ATV at therapeutic levels, despite coadministration with tenofovir [40] . Interestingly, another study in Taiwanese patients undergoing therapeutic drug monitoring who had been switched to ATV without ritonavir from a ATV/r regimen actually found that 16.5% of the patients in the tenofovir group (N = 103), but 35.1% of patients without tenofovir (N = 94) had ATV concentrations below the recommended therapeutic values (P < 0.01). Time to virologic failure was not different between groups [41] . It is important to note that in both studies, patients were only included if they had no history of virologic failure or resistance-associated mutations. A recent meta-analysis of five randomized-controlled trials compared ART regimens including ATV versus ATV/r in treatmentexperienced patients for whom ritonavir was no longer advised. This study reported improved safety outcomes in the groups without ritonavir without sacrificing efficacy, but the authors cautioned that longer-term studies of efficacy and safety were needed [42] .
Pharmacodynamics

HIV-1 protease
The target of ATV is HIV-1 protease. ATV interferes with maturation of the HIV virion by blocking the active site of the HIV-1 protease so that it cannot cleave the viral gag and gag-pol polyproteins (Fig. 1) [43] . There is a high barrier to resistance with PIs, but certain resistanceassociated mutations in HIV-1 protease do confer resistance to ATV and increase susceptibility to the remaining PIs, notably isoleucine to leucine at amino acid residue 50 (I50L), the isoleucine to valine mutation at residue 84 (I84V), and the arginine to serine mutation at residue 88 (N88S). Knowing whether a patient carries one of these mutations is very useful for clinicians to decide the best treatment course [3, 44, 45] .
UGT1A1
Glucuronidation of substrates increases their water solubility and facilitates their excretion in bile and urine. The UDP glucuronosyltransferase (UGT) family of enzymes is responsible for the glucuronidation of a wide variety of endogenous and xenobiotic substrates. Among the 19 functional enzymes of the human UGT super family, only UGT family 1 member A1 (UGT1A1) is known to be capable of glucuronidating bilirubin, a product of heme catabolism. As ATV is a competitive inhibitor of UGT1A1, a common adverse effect in patients administered ATV is elevation of nonglucuronidated (unconjugated) bilirubin, a condition known as hyperbilirubinemia. As UGT1A1 does not metabolize ATV, this relationship appears to be an offtarget PD interaction. Hyperbilirubinemia because of ATV is not necessarily indicative of hepatic injury, but may result in cosmetic jaundice, and there is concern that it may compromise drug adherence in certain patients [46, 47] .
Drug-drug interactions
Many commonly prescribed drugs are metabolized, inhibited, or induced by the main ATV-metabolizing enzymes CYP3A4/5; thus, there is a high potential for drug-drug interactions, especially in older patients, in whom polypharmacy is common, and in patients coinfected with hepatitis C, tuberculosis, or other opportunistic bacterial or fungal infections, a common complication in individuals with HIV [48] . A case series in four HIV-positive patients reported that ATV and ritonavir C min and area under the curve (AUC) were only moderately reduced in patients administered voriconazole, a triazole antifungal agent [49] . A recent study in healthy volunteers reported that coadministration of ATV/r with voriconazole also led to reductions of ATV C min of between 20 and 30% irrespective of the metabolizer phenotype of the primary metabolizing enzyme of voriconazole, CYP2C19. Although CYP2C19 is the primary metabolizing enzyme, voriconazole is also metabolized by CYP3A4 [50] . The study also found that coadministration of voriconazole and ATV/r led to decreased voriconazole exposure in patients with the CYP2C19 extensive metabolizer phenotype and increased voriconazole exposure in patients with the CYP2C19 poor metabolizer phenotype, which the authors attribute to CYP2C19 induction by ritonavir [51] . The FDA-approved drug label for ATV also provides specific dose-scheduling and dosing recommendations for patients who are concomitantly taking H 2 -receptor antagonists, proton-pump inhibitors, antacids, or buffered didanosine because ATV absorption depends on low gastric pH [3, 8, 52] . Other drugs that are extensively metabolized by UGT1A1, such as the cancer drug irinotecan, are contraindicated because of the high potential for toxicity [3, 23] .
Pharmacogenomics of ATV/r UGT1A1
Gilbert's syndrome is characterized by mild and intermittent elevations of bilirubin caused by homozygosity of the c.-53_-52 [TA] 6 > [TA] 7 allele in UGT1A1 at rs8175347 (*28). The UGT1A1*28 allele consists of seven thymidine-adenine (TA) tandem repeats in the promoter region of UGT1A1 where normally there are six (UGT1A1*1 allele). The *28 allele causes a ∼ 50% decrease in UGT1A1 protein expression. Similarly, the *37 ([TA] 8 ) allele also decreases UGT1A1 transcriptional activity relative to *28, whereas the *36 ([TA] 5 ) allele in UGT1A1 leads to increased transcriptional activity relative to *28 [47] . The *36 and *37 alleles are rare in White and Asian populations, but are more common in West and sub-Saharan African populations [53] . The UGT1A1*6 allele (c.211 G > A at rs4148323), which causes a missense mutation (G71R), is more prevalent in individuals of East Asian descent, but has not been found to be associated with ATV-associated hyperbilirubinemia [54] .
The UGT1A1*28/*28 genotype has been repeatedly shown to be associated with hyperbilirubinemia in patients administered ATV and there is some evidence that the homozygous genotype may also be associated with drug discontinuation [29, [54] [55] [56] [57] [58] [59] [60] . Most recently, a study in 321 patients reported an association between the T allele at rs887829 in the promoter region of UGT1A1 (c.-364 C > T) and bilirubin-associated discontinuation. The hazard ratio for bilirubin-related discontinuation for all patients with the TT genotype (vs. CC genotype) was 7.3 [95% confidence interval (CI): 1.7-31.5; P = 0.007]. However, when stratified by race, hazard ratio for discontinuation in White patients (N = 152) was 14.4 (95% CI: 2.6-78.7; P = 0.002), but 0.8 (95% CI: 0.05-12.7; P = 0.87) for Black patients (N = 153). The authors speculate that if jaundice as a result of hyperbilirubinemia is less obvious in individuals with darker skin, it may explain the decrease in bilirubin-associated discontinuation in Black patients compared with White patients [61] . An earlier genome-wide association study (GWAS) of 475 patients administered ATV/r as part of the AIDS Clinical Trial Protocol Group A2502 previously found that the T allele at rs887829 in the promoter region of UGT1A1 (c.-364 C > T) was associated with increased peak bilirubin concentrations (P = 6.4 × 10 -12 ) [62] . The T allele is in almost complete linkage disequilibrium with UGT1A1*28, which would allow for genotyping only at rs887829, thereby facilitating the detection of the UGT1A1*28 allele. An earlier study reported that the TT genotype at rs887829 was associated with a cumulative incidence of bilirubin-related ATV/r drug discontinuation (P = 9.3 × 10 − 14 ) when it was assessed in 481 Black, White, and Hispanic patients [63] .
Cholelithiasis is infrequent among HIV-positive individuals treated with ATV/r, but long-term (>2 years) treatment may increase the incidence of cholelithiasis. A study of 890 Japanese patients showed a positive association between treatment duration greater than 2 years with an increased likelihood of cholelithiasis, although this did not reach statistical significance in multivariate analysis [64] . In line with these findings, a retrospective observational study of 14 patients treated with ATV who had developed complicated cholelithiasis reported that in four patients, 100% of the biliary calculi was made up of ATV [65] . The incidence of cholelithiasis has not been found to differ between patients treated with ATV/r and those treated with other PIs boosted with ritonavir [66] . One retrospective pharmacogenetic study of 910 HIVpositive individuals who had undergone therapeutic drug monitoring and abdominal sonography reported no association between either UGT1A1*28 or rs2032582 (c. c.2677 A > C/T) in ABCB1 (also known as MDR1 2677 A > C/T) with the risk of cholelithiasis [7] .
Nephrolithiasis is also infrequent in patients treated with ATV/r, but incidence may also increase in patients treated over a year [67, 68] . Two studies reported that the incidence of nephrolithiasis was higher in patients treated with ATV/r compared with other PIs (darunavir, fosamprevenir, and lopinavir) with or without ritonavir [69, 70] . A pharmacogenetic study of 71 Japanese patients treated with ATV/r reported that three single nucleotide polymorphisms (SNPs) in high LD within the 3′-untranslated region of UGT1A1 were associated with nephrolithiasis: the CT genotype versus the CC genotype at rs10929303 (c.*211 T > C) [adjusted odds ratio (OR) = 3.7, 95% CI: 1.13-11.9; P = 0.030], the CG genotype versus the CC genotype at rs1042640 (c.*339 G > C) (adjusted OR = 5.8, 95% CI: 1.56-21.3; P = 0.009), and the GG or CG genotypes versus the CC genotype at rs8330 (c.*440 G > C) (adjusted OR = 5.8, 95% CI: 1.56-21.3; P = 0.009). Additional factors associated with an increased risk of nephrolithiasis included elevated serum bilirubin concentrations and hepatitis C coinfection [71] .
Additional UGT1A variants
The structure of the UGT1A locus is complex and involves a shared set of coding exons and alternative first exons for each gene [46] . As the span of the whole UGT1A locus is less than 200 000 bases, variants within the boundaries upstream of the UGT1A gene may be linked to variants in UGT1A1. In a study of HIV-1-positive patients taking ATV/r (N = 106), additional UGT1A variants were found to be associated with the severity of hyperbilirubinemia. Patients were genotyped at rs3806596 (c.861 + 35196 T > C) in UGT1A3 and rs7586110 (c.855 + 44504 T > G) in UGT1A7, both in the respective promoter regions of those first exons. They were also genotyped at a haplotype that results in two amino acid changes in UGT1A7 (UGT1A7
129K/131K
) and this haplotype is the result of several possible single nucleotide changes, which the authors do not differentiate a [46] . rs3806596 CC, rs7586110 GG, and homozygosity of UGT1A7 129K/131K and UGT1A1*28 was designated as the 'homozygous haplotype'. Patients were categorized by the severity of hyperbilirubinemia from grade 0 (< 19 µmol bilirubin/l) to grade 3-4 (≥43 µmol/l bilirubin) and the frequency of the homozygous haplotype was compared between groups as well as with a group of healthy controls. The incidence of the homozygous haplotype in healthy controls was 9.6%, but in individuals with severe (grade 3-4) hyperbilirubinemia, it was 41.2% (P < 0.0001). All six patients with grade 4 hyperbilirubinemia (severe ≥ 85 µmol bilirubin/l) had the homozygous haplotype [55] . When rs3806596, rs7586110, and rs17863778 were analyzed in a large GWAS of 475 patients administered ATV/r (AIDS Clinical Trial Protocol Group A2502), they were not found to be associated with an increased likelihood of developing hyperbilirubinemia after correcting for the presence of the rs887829 T allele in UGT1A1 [62] (Table 1) .
ABCB1, SLCO1B1, NR1I2
The P-glycoprotein transporter mediates the efflux of many xenobiotic substances and its function is therefore an important determinant of drug PKs. Three polymorphisms in ABCB1, rs1045642 (c.3435 A > G), rs2032582 (c.2677 A > C/T), and rs1128503 (c.1236 A > G) have been investigated thoroughly because of their effects on many drugs [72] . Two small studies (N = 88 and 37) reported no association between ATV C trough concentrations in HIV-1-positive patients and rs1045612 [73, 74] or rs2032582 [74] . In 188 HIV-1-positive patients treated with ATV/r, the GG genotype at rs1045642 was associated with increased plasma concentrations of ATV compared with the AA or AG genotype (P < 0.01) and the A allele was associated independently with lower ATV concentrations [59] . When the three ABCB1 SNPs were assessed simultaneously (rs1128503 G, rs2032582 C, and rs1045642 G) in healthy volunteers administered ATV/r, clearance (CL/F in l/h/kg) was fastest in patients with zero GCG copies (0.1) compared with those with one (0.073) or two (0.070) copies of the haplotype (P < 0.03). After controlling for the number of CGC copies, race and sex were no longer associated with ATV CL/F (P = 0.86 and 0.21, respectively) [29] .
In a study that evaluated ATV and ritonavir concentrations in plasma and peripheral blood mononuclear cells in 35 HIV-1-positive patients, the AC and CC genotypes in rs2032582 in ABCB1 were associated with a higher ATV intracellular to plasma concentration ratio (P = 0.007) and significantly lower plasma ATV concentration (P = 0.043). No other SNPs were associated with ATV intracellular or plasma concentrations, although CC and CT at rs4149056 (c.521 T > C) in SLCO1B1 and AG and GG at rs1523130 (c.-1663T > C) in NR1I2 were associated with increased intracellular concentrations of ritonavir [19] . This is supported by the findings of the AIDS Clinical Trial Group A5202 GWAS, which found no association between rs1045642 and rs1128503 in ABCB1, nor in rs4149056 in SLCO1B1 with ATV clearance [62] . Altogether, little evidence suggests a potential association between the G allele at rs1045642 with increased exposure to ATV and more studies would need to confirm this. Two additional studies reported finding no significant association between polymorphisms in ABCB1 with the risk of cholelithiasis or nephrolithiasis [7, 71] and a third found no association with rs2472677 (c.-22-7659C > T) in NR1I2 or rs1045642 in ABCB1 and the likelihood of drug discontinuation in patients administered ATV/r [58] (Table 2) .
Pharmacogenomics of atazanavir without ritonavir UGT1A1
In a single-arm, open-label, two-phase study of 31 HIVnegative volunteers, grouped by genetically determined CYP3A5 expressor status, ATV was administered alone for 7 days, followed by ATV/r for another 7 days, and ATV PKs and bilirubin concentrations were evaluated on days 7 and 14. During the unboosted phase, median increases in indirect bilirubin concentrations were significantly lower in patients with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes compared with patients with the UGT1A1*28/*28 genotype (P < 0.003) [29] .
In a pilot study of HIV-1-positive patients who had been taking ATV/r as part of ART, bilirubin concentrations, immunologic, virologic, and metabolic outcomes were assessed to determine whether a switch to ATV without ritonavir would be beneficial for those patients harboring UGT1A1*28 alleles. Patients who had one or two copies of UGT1A1*28 were switched to the unboosted ATV regimen and had significantly lower total bilirubin when they were evaluated at twelve months (1.82 mg/dl) compared with the baseline (4.09 mg/dl) (P < 0.001). In addition, these differences were accompanied by improvements in lipid profile and hepatic enzymes (λ-glutamyltransferase and transaminases) without alterations in efficacy: HIV-1 RNA was undetectable in the 24 patients who switched and there were no changes CD4 T-cell counts in any patient at 48 weeks [75] (Table 3 ).
CYP3A5
Variability in ATV PKs when it is administered without ritonavir has been attributed to the presence of variants in CYP3A5 that confer functionality when lack of function is more common. Individuals who carry any combination of two nonfunctional alleles are often designated as 'nonexpressors' relative to individuals with one or two functional alleles who are designated 'expressors'. In the aforementioned two-phase study of 31 HIV-negative volunteers administered 400 mg of ATV without ritonavir for the first 7 days of the study, ATV CL/F on day 7 was 1.39 times faster in the 'expressor' group compared with the 'nonexpressor' group (P = 0.045). The minimum concentration (C min ) was lower and half-life was shorter in expressors versus nonexpressors, but this was not significant. Significant differences were not found in in C max or AUC and differences according to expressor status were only observed in the non-African-American (NAA) men and women. However, within the African-American (AA) group, CL/F differences according to CYP3A5 expressor status were not observed in men (N = 6) or women (N = 7), although low numbers make this difficult to interpret with confidence. When controlling for the presence of the GCG haplotype in ABCB1, CYP3A5 expressers still had faster CL/F versus nonexpressors (P = 0.01) [29] .
In a follow-up to that study, 14 of the original plasma samples were reanalyzed to determine how ATV PKs has a CGA at position 131, which encodes an arginine (R), but the combination of the rs17863778 C > A and rs17868324 G > A single nucleotide polymorphisms would result in an AAA codon at position 131 that encodes a lysine (K). AAG also encodes a lysine, but this change would require three changes, rather than two.
related to the ratio of ATV-metabolites to ATV and significant differences were found when comparing between CYP3A5 expressor groups among the AA and NAA patients. Within the NAA group, ATV AUC was 1.8 times higher in CYP3A5 nonexpressors compared with CYP3A5 expressors. ATV AUC was 2.4-fold higher in AA CYP3A5 expressors compared with NAA CYP3A5 nonexpressors. There were no significant differences between CYP3A5 expressors and nonexpressors within the AA group, although there was a consistently higher M1 : ATV ratio within the AA and NAA in the CYP3A5 expressor group compared with the CYP3A5 nonexpressor group [26] .
In a third follow-up study, ATV PK parameters were reevaluated and assessed using a population PK model that incorporated additional clinical and genetic variants (CYP3A4/5, ABCG2, NR1I2, and SLCO1B1). In this study, ATV CL/F was 26% slower in CYP3A5 nonexpressors, 33% slower in patients who carried one or two copies of the ABCB1 GCG haplotype, and 31% lower in patients who carried one or more CYP3A4*1B alleles (P = 0.0074). The authors also found an interaction between CYP3A5 expressor status and genotype at rs2472677 in NR1I2.
Compared with the CT and TT genotypes, the CC genotype was associated with a 37% lower CL/F in CYP3A5 nonexpressors and a 63% faster CL/F in CYP3A5 expressors. Additional demographic factors that were associated with lower CL/F were African-American ethnicity (33% decrease), female sex (25% decreased), and age (1.7% decrease/year over age 30) [18] .
A subset of the retrospective Prospective Evaluation of Antivirals in a Resource Limited Settings study (PEARLS) included 69 treatment-naive HIV-positive patients treated with ATV without ritonavir from the United States, Peru, and South Africa. A single plasma sample was collected at 4 and 8 weeks and population PK modeling was used to predict CL/F and C 24 , metabolite to parent compound ratios (M1 : ATV and M2 : ATV) as well as the likelihood of virologic failure by CYP3A5 expressor status, or genotype. CYP3A5 expressors showed a statistically significant decrease in the likelihood of virologic failure (OR = 0.95, 95% CI: 0.89-1) compared with CYP3A5 nonexpressors (OR = 0.73, 95% CI: 0.57-0.94; P = 0.026) at 72 weeks. No statistically significant associations were found between ATV CL/F, C 24 , M1 : ATV, or M2 : ATV with CYP3A5 expressor status after adjusting for race and sex, or in ranked 
Slower CL/F of ATV is associated with more copies of the 'GCG'
The G allele is not associated with ATV C trough vs. the A allele [73, 74] The A allele is associated with lower plasma ATV concentrations vs. the G allele [59] The G allele is not associated with ATV clearance vs. the A allele [62] The G allele is not associated with drug discontinuation vs. the A allele [58] N = 88, observational; N = 103, observational N = 118, observational N = 443, subset of phase IIIb equivalence, genome-wide association study N = 121 observational c.2677 A > C/T (rs2032582)
The C + T alleles are not associated with the risk of cholelithiasis vs. the A allele [7] The C + T alleles are not associated with ATV C trough vs. the A allele [74] The AC + CC genotypes are associated with higher ATV intracellular: plasma concentrations as well as lower plasma ATV concentrations [19] The C/T alleles are not associated with the risk of nephrolithiasis vs. the A allele analysis. When patients were grouped by genotype rather than by CYP3A5 status, ATV CL/F was found to be significantly faster for patients with the CYP3A5*1/*1 compared with CYP3A5*1/*3 and CYP3A5*3/*3 (P = 0.0006) genotypes and the difference with *1/*3 when adjusting for race and sex (P = 0.001). Surprisingly, the CYP3A5*1/*6 genotype was associated with faster CL/F [15.7 ng/ml (14.6-16.8)] compared with the CYP3A5*1/*1 genotype [12.4 ng/ml (11.6-13.4)] (P = 0.004) even after adjusting for race and sex. CYP3A5 genotypes were not associated with C 24 , or M1 : ATV or M2 : ATV after adjusting for race and sex or in ranked analysis [28] (Table 4) .
ABCB1, SLCO1B1, NR1I2
In a two-part study, in which healthy volunteers were administered ATV, followed by ATV/r, several PK parameters such as CL/F and C min of ATV were determined. During the phase in which ATV was administered without ritonavir, ATV CL/F was reported to be faster and C min was reported to be lower, respectively, in patients with zero versus one or two copies of the GCG haplotype in ABCB1 (P < 0.007 for CL/F and P < 0.02 for C min ). Homozygosity for the GCG haplotype in ABCB1 was also associated with a higher bilirubin concentration compared with zero copies (P = 0.036) [29] . In a separate study of 74 White patients administered ATV only, only the G allele at rs1045642 in ABCB1 was found to be associated with higher median plasma concentrations of ATV and the median ATV C min was also higher in patients with the GG genotype compared with the AA and AG genotypes (P < 0.01). A greater proportion of patients with the GG genotype (92%) also had bilirubin concentrations above the upper limit of normal (>1.3 mg/dl) compared with patients with the AG (67%) (P < 0.05) or AA genotypes (41%) (P < 0.05) [17] .
Polymorphisms in NR1I2, SLCO1B1, and ABCB1 were also evaluated in the PEARLS study. That study included patients from Peru, South Africa, and the USA (N = 69) of various ethnicities who were coadministered unboosted ATV with didanosine-EC + emtricitabine. In that study, the CT genotype at rs2472677 in NR1I2 was associated with a significant decrease in ATV C 24 (48.4 ng/ml) compared with either the CC (126.8 ng/ml) or TT genotypes (172.6 ng/ml) (P = 0.01 and P = 0.007, respectively) even after adjustment for race and sex.
Patients with two copies of the ABCB1 GCG haplotype had decreased ATV C 24 compared with patients with one, although the association did not remain significant after adjusting for race and sex or in ranked analysis. Neither rs2306283 nor rs4149056 in SLCO1B1 was associated with CL/F, C 24 , M1 : ATV, or M2 : ATV [28] . This is contradicted by two other studies in which HIV-1-positive patients were administered ATV without ritonavir. In the first study (N = 109; 26% female, ethnicities unknown), the TT genotype at rs2472677 in NR1I2 was associated with lower median trough concentrations of ATV (C trough ) (34 vs. 152 ng/ml; P = 0.001) and an increased likelihood that ATV concentrations were below the minimum effective concentration of 150 ng/ml in two cohorts (OR = 18, 95% CI: 2.1-153.9; P = 0.008). In addition, tenofovir was not associated with C trough in either group [21] . In the second study, which included many patients from the same cohort as well as a new cohort (N = 182; 64% male), population PK modeling was used to show that the CT and CC genotypes at rs2472677 in NR1I2 were associated with a 17.2% decrease in CL/F compared with the TT genotype [22] .
Finally, a randomized-controlled pilot study investigated whether pharmacogenetic-based dosing could improve the ATVs PK profile in patients switched to 400 mg ATV without ritonavir because of issues of toxicity, tolerability, or dose simplification. The pharmacogenetic-guided dosing arm (N = 40) was assigned to a dosing schedule guided by genotypes at three different SNPs: rs2472677 in NR1I2, rs1045642 in ABCB1, and rs4149056 in SLCO1B1. The TT genotype at rs2472677, AA, or AG genotypes at rs1045642, and the TT genotype at rs4149056 were considered 'unfavorable genotypes' References [18, 26, 29] are all reanalyzed data from the same volunteer participants.
because they had previously been associated with decreased exposure to ATV. Each unfavorable genotype was assigned one point and patients with two to three points received twice-daily 200 mg doses of ATV to improve ATV exposure, whereas those with zero or one point received 400 mg ATV once daily. Patients in the non-pharmacogenomic-guided dosing arm (N = 40) received a once-daily dose of 400 mg of ATV. The geometric mean of ATV C trough in the pharmacogenetic arm was 253 ng/ml (150-542) versus 111 ng/ml in the standard-dose arm. In addition, 75.7% of the patients in the pharmacogenetic arm had ATV C trough concentrations within the therapeutic range (>150 ng/ml) compared with only 38.9% of patients in the standard-dose arm (relative risk = 4.89, 95% CI: 1.79-13.38; P = 0.001) [40] . Current evidence, along with the pharmacogenetic-guided dosing study, may support the association between the TT genotype at rs2472677 in NR1I2 and the G allele at rs1045642 in ABCB1 with increased ATV exposure when it is administered without a PK enhancer (Table 5) .
Conclusion
The findings summarized here are limited by the small cohort sizes and the over-representation of White, male patients in most studies, thereby minimizing the extent to which they may be extrapolated to more diverse populations. Future studies in larger and more diverse cohorts could help to explain why CYP3A5 appears to affect unboosted ATV differently in Black versus White patients. In addition, the incorporation of genetic variants known to affect ritonavir PKs into a dosing algorithm that includes genetic variants known to affect ATV PK may help to more precisely estimate dosing strategies for individual patients, although dose reductions in ATV and/or ritonavir have also shown promise in some patients [76] . There is also good and consistent evidence of an association between UGT1A1 rs8175347 (*28, *37) and the TT genotype at rs8175347 with an increased likelihood of hyperbilirubinemia in patients administered ATV/r, as well as an increased likelihood of drug discontinuation. The Clinical Pharmacogenetic Implementation Consortium guidelines for pharmacogenomic prescribing of ATV recommend discussing the high likelihood of developing jaundice in patients homozygous for these alleles as well as considering alternative ART regimens unless jaundice is not of concern to the patient [60] . Other variants in other genes may influence the severity of hyperbilirubinemia or nephrolithiasis, but have not been replicated and are not yet Slower CL/F and higher C min of ATV is associated with more copies of the 'GCG' haplotype in ABCB1 (0 > 1 > 2). Homozygosity of the 'GCG' haplotype is associated with increased bilirubin concentrations vs. one or zero copies of the 'GCG' haplotype [29] . Homozygosity of the 'GCG' haplotype was not associated with ATV C 24 after adjusting for race and sex in ranked analysis [28] N = 31, single-arm, open-label 2-phase N = 69, subset retrospective observational c.3435 A > G (rs1045642)
The G allele is associated with higher median plasma concentrations of ATV vs. the A allele. The GG genotype is also associated with higher median C min and bilirubin concentrations above the upper limit of normal (upper limit of normal > 1.3 mg/dl) vs. the AA and AG genotypes [17] . Incorporation of the genotypes into a PGx dosing algorithm is associated with improved ATV C trough concentrations. The AA + AG genotypes were associated with lower ATV exposure vs. the GG genotype and were given 2 × 200 mg daily doses instead of 1 × 400 mg daily dose [40] . The CC genotype is associated with slower ATV CL/F in CYP3A5 nonexpressors and more rapid ATV CL/F in CYP3A5 expressors vs. the CT and TT genotypes [18] The CT genotype was associated with a significant decrease in ATV C 24 compared with either the CC or TT genotypes even after adjustment for race and sex [28] The TT genotype is associated with decreased ATV C trough and increased likelihood that concentrations were below the minimum effective concentration vs. CT + CC genotypes [21] The CT + CC genotypes are associated with faster ATV CL/F vs. the TT genotype [22] Incorporation of the genotypes into a PGx dosing algorithm is associated with improved ATV C trough concentrations. The TT genotype was associated with lower ATV exposure vs. the CT + CC genotypes and were given 2 × 200 mg daily doses instead of 1 × 400 mg daily dose [40] . clinically actionable. An effective pharmacogenetic-guided dosing strategy will likely require larger studies in more diverse cohorts to uncover additional genetic and nongenetic factors, such as race, sex, concomitant drug use, or coinfection, to improve drug adherence and minimize adverse events in patients receiving ATV.
